1

Identity

Bristol-Myers Squibb, S.A.U.

A28042463

€382M

Amount awarded, solo awards 2016–2026

Amount awarded by year
YearAmountDistribution
2026*€152.1M
2025€79.8M
2024€61.7M
+ regional platforms
2023€11.2M
2022€23.6M
2021€30.8M
2020€4.4M
2019€14.4M
2018—
2017€2.9M
2016€0.7M
*2026: data to 31 October · 92 contracts in 2026 · Since 2024 this also includes data from regional platforms. · Solo awards, excluding JVs · Framework agreements at €0 · €M
445
Contracts (lots)
across 302 tenders
38
Buyers
95%
Single bidder
2
Awards in UTEs
not in the total

In figures

Volume

Between 2016 and 2026 it won 445 contracts worth €382M on its own, with 38 buyers. Its 2 joint-venture (UTE) contracts are shown separately.

Price

It has fewer than 3 comparable awards, too few to compute its median discount.

Competition

Since 2024, 0% of its comparable value was won with a discount and against other bidders. It was the only bidder in 95% of its contracts (2016–2026).

Renewals

64 contracts (€29.1M) come up for tender again in the next 24 months.

A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Bristol-Myers Squibb, S.A.U.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Bristol-Myers Squibb, S.A.U.'s share.

Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage

2

Its discounts

The discount at which it wins contested contracts, year by year.

There are no contested awards to analyse. Of its 445 contracts, 266 are call-offs under framework agreements and 88 cannot be compared against their budget.

Framework call-offs 266 · Single bidder 5 · Non-competitive procedure 86 · No comparable budget 88 · Contested, comparable 0

Where it wins, and at what discount

In the report · these discounts, one by one

Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.

Request the report →

Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.

3

How it wins

Whether it wins with or without competition.

Competition and pricing

100% of the comparable value since 2024 (€2.59M of €2.59M) was won at the tender price and without other bidders.

With a discount
0%
single bidder · 0
0%
multiple bidders · 0
At the tender price
100%
single bidder · 5 · €2.59M
0%
multiple bidders · 0

Comparable: 5 awards with a published budget and bidder count (€2.59M of €294M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.

Award procedure

Between 2016 and 2026, 83.4% of the value was awarded through negotiated without publicity procedure (57.6% of contracts); followed by Other (6.4%) and Based on a framework agreement (6.2%).

Negotiated without publicity · 83.4%
Open
Restricted
Competitive procedure with negotiation
Based on a framework agreement
Negotiated without publicity
Other
4

Upcoming tenders and main buyers

When its contracts come back and who it sells to.

When its contracts come back

In the next 24 months 64 of its contracts come up for tender again, worth €29.1M.

Expected endBuyerValue
2026Hospital Universitario de Fuenlabrada€262k
2026Hospital Universitario Clínico San Carlos€236k
2026Hospital Universitario Clínico San Carlos€35.0k
2026Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad—
2026Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad—

and 59 more in the next 24 months · the report includes them all

Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.

Who they sell to
BuyerContractsValue, €Period
OSAKIDETZA - Servicio Vasco de Salud -Director General17142 M2024–2026
Gerencia de Servicio Sanitarios de Fuerteventura19543 M2019–2026
Servicio Andaluz de Salud4842 M2024–2026
Servicio Murciano de Salud - Junta de Compras3236 M2021–2025
Subsecretaría de la Consellería de Sanidad y Salud Pública922 M2022–2025

and 33 more buyers

Sector activity
Top CPV codes — the EU classification system that identifies the type of works, services or supplies covered by each contract.

Between 2016 and 2026, 99.2% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 433 contracts); followed by Repair & maintenance (CPV 50), with 0.8%.

Medical & pharmaceuticals
99.2%433 contracts
Repair & maintenance
0.8%1 contract
5

Recent awards

The evidence behind every insight in the report.

Latest 5 completed contracts (of 135)
Contracts whose expected completion date has passed.
DateContractBuyerBiddersValue
06/07/2026Suministro de Lisocabtagen Maraleucel "Emergencia".Servicio Cántabro de Salud1—
06/07/2026Suministro de Lisocabtagen Maraleucel "Emergencia".Servicio Cántabro de Salud1—
03/07/2026Suministro De Medicamentos De Uso Humano Tipo Ii (Exclusivos), Con Destino Al Servicio De Farmacia …Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria1€20.5k
02/07/2026Suministro de Lisocabtagen Maraleucel "Emergencia".Servicio Cántabro de Salud1—
18/06/2026Suministro de medicamentos de uso humano tipo II(exclusivos), lote 63, con destino al servicio de f…Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria1€6.58k
Full report on Bristol-Myers Squibb, S.A.U.
Includes: its discount by buyer and sector · winning discounts by buyer and year · how it wins with each buyer · contract renewal calendar. The complete register of its awards in the last three full calendar years and the current year to date, in Excel.
€50 + VAT · VAT is calculated at payment according to your country. You will receive it in PDF and Excel by email within one working day. Every report is reviewed by a person before it is sent to you.
Order the report